Biology & Medicine is a peer-reviewed open-access journal sponsored
by the China Anti-cancer Association (CACA), which is the leading
professional society of oncology in China, and Tianjin Medical
University Cancer Institute and Hospital (TMUCIH). Published quarterly,
the journal provides innovative and significant information on
biological basis of cancer, cancer microenvironment, translational
cancer research, and all aspects of clinical cancer research. The
journal also publishes significant perspectives on indigenous cancer
types in China. The journal adheres to the Recommendations for the
Conduct, Reporting, Editing, and Publication of Scholarly Work in
Medical Journals, issued by the International Committee for Medical
Journal Editors (ICMJE) and the guidelines of Committee on Publication
Ethics (COPE).
Aims and Scope
Cancer
Biology & Medicine is dedicated to reporting latest advances in
cancer research around the world by presenting high quality articles,
especially on translational cancer research, to bridge the gap between
basic and clinical cancer research. Meanwhile, the journal promotes
academic exchange in cancer area between China and the rest of the world
to keep cancer researchers and clinicians updated with current
knowledge of novel findings and recent advances in oncology. The scope
covers the following topics:
● Cancer genetics
● Cancer and stem cell biology
● Molecular and clinical immunology
● Cancer prevention and epidemiology
● Cancer biomarkers
● Radiation oncology
● Oncology clinical trials
● Mechanisms of drug sensitivity and resistance
● Targeted therapy and immunotherapy
● Multidisciplinary treatment and personalized medicine
AUDIENCE
Cancer
Biology & Medicine endeavors to appeal a diverse audience engaged
in cancer research and subspecialties in clinical oncology. Readers may
include, but not limited to, investigators, physicians, surgeons and
nurses in cancer research areas, medical students, and other relevant
health care professionals.
CONTENT CATEGORIES
Original Article, Editorial, Perspective, Review, Minireview, Letter to the Editor, Practice Guideline, and MDT Case Study.
INDEXING INFORMATION
Cancer
Biology & Medicine is indexed in SCIE, PubMed/PubMed Central,
BIOSIS Previews, EMBASE, SCOPUS, EBSCO, DOAJ, and Chemical Abstracts.
EDITORIAL POLICIES
Authorship and Contributorship
Authorship
credit should be based on 1) substantial contributions to conception
and design, acquisition of data, or analysis and interpretation of data;
2) drafting the article or revising it critically for important
intellectual content; and 3) final approval of the version to be published. The manuscript’s
content and its submission for publication should be approved by all
authors who should sign off in the author form prior to submission.
Revisions and final version should be
approved by all authors. Contributors who do not meet the criteria for
authorship should be listed in the Acknowledgments section.
Except
for ensuring that authors are appropriately listed and providing
information on the specific contributions each author has made to the
article, the corresponding author is also required to offer the Open
Researcher and Contributor Identifier (ORCID) ID before proceeding with
submission. He/she could register an account of ORCID via this link:
https://orcid.org/. By the way, please be aware that all communication
during the submission and publishing process will be sent to the
corresponding author. Co-first authors and co-corresponding authors are
acceptable, but no more than 2. In cases with co-corresponding authors, a
primary one must be designated as the point of contact responsible for
all communication and will be listed firstly.
Ethics Involving Humans and Animals
The
welfare of animals used for research must be respected. Animal
experiments should abide by the institutional and national guide for the
care and use of laboratory animals. For primary research manuscripts in
Cancer Biology & Medicine reporting experiments on animals, the
authors must confirm that all experiments were performed in accordance
with relevant guidelines and regulations. Manuscripts must include a
statement in materials and methods section that the research has been
reviewed and approved by institutional ethical committee before
conduction.
Experiments
on human subjects should follow the Helsinki Declaration (as revised in
2013) and should be approved by an ethics committee. Concerning privacy
and/or security of personal information, informed consents and
permissions must be obtained in regard to case details, personal
information, and/or images used. When reporting studies that involve
human participants, authors should include a statement that the studies
have been approved by the appropriate institutional and/or national
research ethics committee and have been conducted in accordance with
Declaration of Helsinki. For manuscripts reporting biomedical research
involving human subjects, a statement that the informed consent was
obtained from each subject is required. If the study is a clinical
trial, the trial must be registered in an appropriate registry prior to
the start of the trial. Authors should provide ClinicalTrials.gov
Identifier in the manuscript.
For
all research involving human subjects, informed consent should be
obtained from participants or their legal guardian and a statement to
this effect should appear in the manuscript. Informed consent must
comply with all applicable laws and regulations concerning the privacy
and/or security of personal information. Patients' names, initials,
social security numbers, dates of birth or other personal or identifying
information should not be used. Images of patients should not be used
unless the information is essential for scientific purposes and explicit
permission has been given as part of the consent. Identifying details
should be omitted if they are not essential.
Conflict of Interest
Conflict of interest exists when an author (or the author’s institution), reviewer, or editor has any financial or personal relationships that may inappropriately influence (bias) his or her actions. Cancer Biology
& Medicine requires all authors to disclose any relationship that
might result in an actual, potential, or perceived conflict of interest
about the manuscript submitted for review. Reviewers and editors should
also disclose all relationships that may undermine the credibility of
the publication process. Conflict of Interest Statement should be
written as a section before References.
Exclusive Submission
Manuscripts
are considered for review only if no part of the work has been
previously published in print or electronically. Previous publication of
an abstract in the proceedings of meetings does not preclude whole
manuscript submission for publication, but full disclosure should be
made. At submission, the corresponding author is responsible to attest
that the manuscript, in whole or in part, is not under consideration, in
press, or published in any other publication or electronic medium.
Copyright and Permissions
If
a manuscript includes copyrighted materials of others, authors must
obtain written permission from the copyright owners and indicate the
sources in the article. The written permission should be simultaneously
submitted with the manuscript.
Checking for Scientific Misconduct
Cancer
Biology & Medicine has an obligation to ensure that its published
articles are accurate and adheres to the highest ethical standard.
Editors check all submissions using CrossCheck. In the cases of
plagiarism, redundant or duplicate publication, the journal will send a
letter of reprimand to the authors’ institution, publish a notice of
misconduct and formally retract the published manuscript. The journal
will remove further association with the involved authors and
institutions.
Peer Review
After
initial review by the editor or sometimes by an editorial board member,
manuscripts without sufficient priority for publication will be
editorially rejected within 7 days. Those qualifying for peer review
will be sent to at least two expert reviewers for unbiased, independent
and critical assessment. Reviewers are asked to provide an overall
recommendation supported by detailed comments on the quality and
originality of the science as well as the applicability and impact of
the reported results and conclusions. In addition, the scientific
validity of statistical analysis and data of clinical trial articles
will be evaluated by reviewers. Peer reviewers’ identities are kept
confidential, but authors’ information will be provided to the
reviewers. The editors endeavor to reach decisions on these papers
within four weeks from the original submission date. We allow authors
two weeks for general revision and one month for major revision.
Accepted papers will be published in print within four months of
acceptance.
Embargo Policy
Scientific
information in a manuscript which is under consideration or in press in
Cancer Biology & Medicine may not be discussed with the media
before publication. Preliminary reporting to public media, governmental
agencies, or manufacturers should not jeopardize publication, and should
be discussed with and approved by the editor in advance.
Corrections and Retractions
Corrections
to articles after online publication will only be made for errors that
compromise the scientific record, such as a mistake in an author’s name,
or that substantially impact the meaning or interpretation of the data
but that do not compromise the overall results or conclusions of the
article. A correction should be published as soon as reasonably
possible.
Retractions
refer to an article in its entirety that is the result of a pervasive
error, nonreproducible research, scientific misconduct, or duplicate
publication. In instances of retraction due to misconduct, the
corresponding author’s institute and funding agency will be notified,
